Novel Insights on the Current and Emerging Treatment
Strategies of Castration Resistant Prostate Cancer (CRPC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 20, 2018 to April 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Astellas Scientific and Medical Affairs, Inc. and Medivation and
Bayer HealthCare Pharmaceuticals

Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Screening for CRPC requires measuring PSA levels which are the most common biomarker for prostate cancer. High PSA values indicate an increased probability of the tumor existing. Fortunately, the treatment paradigm has dramatically changed over the past decade with emerging therapies that have shown to improve patient outcomes, survival, and quality of life. Chemotherapy and immunotherapy remain the mainstay of treatment in the first and second line setting while recent advances are being used to better treat the disease, at all stages. Updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, and biomarkers, based on appropriate patient selection criteria, are revolutionizing the way clinicians treat and manage CRPC.

Upon Completion of this activity, participants will be able to:

  • Assess the clinical efficacy and safety data on therapies currently under investigation for the treatment of CRPC

  • Explore the clinical data for therapies currently available for the treatment of CRPC, including systematic and biologic agents

  • Discuss the appropriate treatment algorithms for CRPC patients that may include the use of combination and sequencing strategies

  • Identify the challenges and barriers for optimal care in patients with CRPC

  • Evaluate strategies to manage treatment-related side effects in patients with CRPC

Faculty: Channing Paller, MD
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Hospital and Sibley Memorial Hospital


Dr. Paller receives research support from Bayer and Lilly USA LLC. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Astellas Scientific and Medical Affairs, Inc. and Medivation and
Bayer HealthCare Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue